Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Trends Pharmacol Sci. 2009 Jan;30(1):41-7. doi: 10.1016/j.tips.2008.10.005. Epub 2008 Nov 29.

Neurobiology and treatment of Parkinson's disease.

Author information

  • University Department of Clinical Neurosciences, University College London, London NW3 2PF, UK. a.schapira@medsch.ucl.ac.uk

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease and is an important cause of chronic disability. Numerous important advances have been made in our understanding of the aetiopathogenesis, pathology and clinical phenomenology of this disease, and these have underpinned advances in symptomatic treatment and the prospect that these might be extended into interventions that will slow progression. It is notable that the continuing characterisation of the downstream biochemical consequences of the genetic causes of PD serves only to reinforce this notion. Progress in the management of PD has continued, particularly in timing of drug initiation and the sequence and combinations in which drugs are used to improve long-term outcome and reduce drug-induced complications. Particular progress has been made in the field of neuroprotection, where novel therapies and clinical trial designs are being tested. This review will focus particularly upon this area.

PMID:
19042040
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk